Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial - PubMed (original) (raw)
Clinical Trial
. 2003 Jun 4;289(21):2819-26.
doi: 10.1001/jama.289.21.2819.
Affiliations
- PMID: 12783912
- DOI: 10.1001/jama.289.21.2819
Clinical Trial
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial
Paul S Aisen et al. JAMA. 2003.
Abstract
Context: Laboratory evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer disease (AD), along with epidemiological evidence, suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) may favorably influence the course of the disease.
Objective: To determine whether treatment with a selective cyclooxygenase (COX) -2 inhibitor (rofecoxib) or a traditional nonselective NSAID (naproxen) slows cognitive decline in patients with mild-to-moderate AD.
Design: Multicenter, randomized, double-blind, placebo-controlled, parallel group trial, with 1-year exposure to study medications.
Setting: Forty ambulatory treatment centers affiliated with the Alzheimer's Disease Cooperative Study consortium.
Participants: Participants with mild-to-moderate AD (Mini-Mental State Examination score of 13-26) were recruited from December 1999 to November 2000 using clinic populations, referrals from community physicians, and local advertising. Stable use of cholinesterase inhibitors, estrogen, low-dose aspirin, and vitamin E was allowed. Participants with inflammatory diseases that might respond to the study medications were excluded. Of 474 participants screened, 351 were enrolled.
Interventions: Once-daily rofecoxib, 25 mg, or twice-daily naproxen sodium, 220 mg, or placebo.
Main outcome measures: The primary outcome measure was the 1-year change in the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) subscale score. Secondary outcome measures included the Clinical Dementia Rating scale sum-of-boxes, the Neuropsychiatric Inventory, the Quality of Life-AD, and the time to attainment of significant end points (4-point decline from baseline ADAS-Cog score, 1-step worsening on the global Clinical Dementia Rating scale, 15-point decline on the ADCS activities of daily living inventory, institutionalization, or death).
Results: The 1-year mean (SD) change in ADAS-Cog scores in participants treated with naproxen (5.8 [8.0]) or rofecoxib (7.6 [7.7]) was not significantly different from the change in participants treated with placebo (5.7 [8.2]). Results of secondary analyses showed no consistent benefit of either treatment. Fatigue, dizziness, and hypertension were more commonly reported in the active drug groups, and more serious adverse events were found in the active treatment group than in the placebo group.
Conclusion: The results of this study indicate that rofecoxib or low-dose naproxen does not slow cognitive decline in patients with mild-to-moderate AD.
Comment in
- Nonsteroidal anti-inflammatory drugs and Alzheimer disease: what's next?
Launer LJ. Launer LJ. JAMA. 2003 Jun 4;289(21):2865-7. doi: 10.1001/jama.289.21.2865. JAMA. 2003. PMID: 12783919 No abstract available. - Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer's disease.
Jacoby R. Jacoby R. Evid Based Ment Health. 2003 Nov;6(4):110. doi: 10.1136/ebmh.6.4.110. Evid Based Ment Health. 2003. PMID: 14585783 No abstract available.
Similar articles
- Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study.
Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC; Rofecoxib Protocol 091 Study Group. Reines SA, et al. Neurology. 2004 Jan 13;62(1):66-71. doi: 10.1212/wnl.62.1.66. Neurology. 2004. PMID: 14718699 Clinical Trial. - Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR, Sperling RS, Reicin A, Gertz BJ. Weir MR, et al. Am Heart J. 2003 Oct;146(4):591-604. doi: 10.1016/S0002-8703(03)00398-3. Am Heart J. 2003. PMID: 14564311 Review. - A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA; Rofecoxib Protocol 078 study group. Thal LJ, et al. Neuropsychopharmacology. 2005 Jun;30(6):1204-15. doi: 10.1038/sj.npp.1300690. Neuropsychopharmacology. 2005. PMID: 15742005 Clinical Trial. - Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Jordan F, Quinn TJ, McGuinness B, Passmore P, Kelly JP, Tudur Smith C, Murphy K, Devane D. Jordan F, et al. Cochrane Database Syst Rev. 2020 Apr 30;4(4):CD011459. doi: 10.1002/14651858.CD011459.pub2. Cochrane Database Syst Rev. 2020. PMID: 32352165 Free PMC article. - What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC. Hochberg MC. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Clin Exp Rheumatol. 2001. PMID: 11695246 Review.
Cited by
- Selective COX-2 Inhibitors as Neuroprotective Agents in Traumatic Brain Injury.
Hiskens MI, Schneiders AG, Fenning AS. Hiskens MI, et al. Biomedicines. 2024 Aug 22;12(8):1930. doi: 10.3390/biomedicines12081930. Biomedicines. 2024. PMID: 39200394 Free PMC article. Review. - Osteoarthritis, osteoarthritis treatment and risk of incident dementia: a prospective cohort study based on UK Biobank.
Guo R, Ou YN, Ma LY, Tang L, Yang L, Feng JF, Cheng W, Tan L, Yu JT. Guo R, et al. Age Ageing. 2024 Aug 6;53(8):afae167. doi: 10.1093/ageing/afae167. Age Ageing. 2024. PMID: 39108220 Free PMC article. - A Fast-Binding, Functionally Reversible, COX-2 Radiotracer for CNS PET Imaging.
Placzek MS, Wilton DK, Weïwer M, Manter MA, Reid SE, Meyer CJ, Campbell AJ, Bajrami B, Bigot A, Bricault S, Fayet A, Frouin A, Gergits F, Gupta M, Jiang W, Melanson M, Romano CD, Riley MM, Wang JM, Wey HY, Wagner FF, Stevens B, Hooker JM. Placzek MS, et al. ACS Cent Sci. 2024 Apr 25;10(5):1105-1114. doi: 10.1021/acscentsci.3c01564. eCollection 2024 May 22. ACS Cent Sci. 2024. PMID: 38799654 Free PMC article. - Insights into amyloid precursor protein target through PPI network analysis.
Grewal A, Sheokand D, Chauhan R, Saini V, Kumar A. Grewal A, et al. Bioinformation. 2024 Feb 29;20(2):140-145. doi: 10.6026/973206300200140. eCollection 2024. Bioinformation. 2024. PMID: 38497073 Free PMC article. - Study Partner Type and Adverse Event Reporting in Mild-to-Moderate Alzheimer's Disease Clinical Trials.
Lu TV, Grill JD, Gillen DL; Alzheimer’s Disease Cooperative Study. Lu TV, et al. J Alzheimers Dis. 2024;98(2):729-738. doi: 10.3233/JAD-231283. J Alzheimers Dis. 2024. PMID: 38427487 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials